Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study

Departments of Dermato-Allergology Cardiology, Copenhagen University Hospital Gentofte, Hellerup, Denmark Research Centre for Prevention and Health, Copenhagen University Hospital Glostrup, Glostrup, Denmark.
International journal of dermatology (Impact Factor: 1.31). 04/2012; 52(6). DOI: 10.1111/j.1365-4632.2011.05408.x
Source: PubMed


Background Epidemiological data have established an association between cardiovascular disease and psoriasis. Only one general population study has so far compared prevalences of cardiovascular risk factors among subjects with psoriasis and control subjects. We aimed to determine the prevalence of cardiovascular risk factors in subjects with and without psoriasis in the general population.
Methods During 2006–2008, a cross-sectional study was performed in the general population in Copenhagen, Denmark. A total of 3471 subjects participated in a general health examination that included assessment of current smoking status, weight, height, waist and hip circumferences, systolic and diastolic blood pressures, resting heart rate, and plasma lipids, hemoglobin A1c, fasting glucose, and insulin levels.
Results Physician-diagnosed psoriasis was reported by 238 (7.1%) of 3374 participants. There were no differences between subjects with and without psoriasis with regard to traditional cardiovascular risk factors.
Conclusions Our results contrast with the hitherto-reported increased prevalence of metabolic syndrome in subjects with psoriasis in the general US population. However, our results agree with those of other previous studies in which the association between mild psoriasis and cardiovascular risk factors is often non-significant. Further controlled research is needed to describe the prevalence of cardiovascular risk factors in subjects with mainly mild to moderate psoriasis in the general population.

Download full-text


Available from: Peter Jensen, May 11, 2014
20 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Psoriasis is an inflammatory autoimmune disease that affects the skin. Recently, psoriasis and its consequential lifestyle and dietary habits have been associated with increased risks for cardiovascular diseases. This article discusses the connection between cardiovascular disorders and psoriasis and the effects of available treatment options on cardiovascular risk. A PubMed search revealed 11 articles that were analyzed for information regarding this association, its effects, and potential courses of treatment. Both the presence and severity of psoriasis increases the risk for cardiovascular disorders and co-morbidities. Forty percent of psoriasis patients met metabolic syndrome criteria as compared with 23 % of non-psoriasis control subjects. Rate ratios for atrial fibrillation are correlated with the severity of psoriasis; patients with severe and mild psoriasis produced rate ratios of 1.63 and 1.31, respectively. Studies also show an increase in the risks for myocardial infarction, atherosclerosis, ischemic stroke, and other cardiovascular disorders. The exact mechanisms behind this affiliation are still uncertain; however, the psychological and physiological effects of psoriasis and the overlapping pathogenesis behind atherosclerosis and psoriasis may play a role. Since the risk for cardiovascular disorders increases with the presence and severity of psoriasis, psoriasis treatment should not only address the disease and its symptoms, but also its co-morbidities. Recent National Psoriasis Foundation (NPF) guidelines have provided recommendations for psoriasis patient care. Histories of co-morbidities, screenings for potential diseases, increased exercise, decreased alcohol consumption, and smoking cessation should be implemented. Unfortunately, while there are data for the increased risk for cardiovascular diseases within psoriasis patients, there are presently no data stating that increasing cardiovascular screening rates in patients produces a significant difference.
    American Journal of Clinical Dermatology 02/2013; 14(1):1-7. DOI:10.1007/s40257-012-0005-5 · 2.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previous studies have shown a higher prevalence of metabolic syndrome in patients with psoriasis compared to controls. However, little attention has been paid to the effect of systemic anti-psoriatic drugs on the metabolic syndrome. The aim of this study was to investigate the association between psoriasis and the metabolic syndrome, by comparing untreated patients with psoriasis and population based control. We conducted a hospital-based case-control study that included 122 untreated patients with plaque psoriasis and 122 age- and gender-matched controls. There was no significant difference in the prevalence of the metabolic syndrome between the patients with psoriasis (24.6 %) and the controls (22.9 %) (OR 1.095, 95 % CI 0.607-1.974). Among the components of the metabolic syndrome only hypertriglyceridemia and abdominal obesity were associated with psoriasis. The psoriatic patients with metabolic syndrome had a higher mean age (p = 0.001), and higher mean BMI (p = 0.001) compared with the psoriatic patients without metabolic syndrome. The metabolic syndrome was not associated with the severity of psoriasis. Untreated patients with psoriasis have no significantly higher prevalence of the metabolic syndrome than healthy controls. Our data suggest that systemic antipsoriatic drugs may play an important role in the pathogenesis of the metabolic syndrome.
    Journal der Deutschen Dermatologischen Gesellschaft 12/2013; 11(12):1169-1175. DOI:10.1111/ddg.12193 · 2.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Questions remain concerning to what extent age and gender may modify the suggested association between psoriasis and the metabolic syndrome in a general population.Objectives To investigate the association between psoriasis and the metabolic syndrome within a large population-based cohort by age and gender.MethodsA cross-sectional study including 10,521 participants age 30-79 years from the Tromsø Study cohort was performed; 1,137 participants reported lifetime psoriasis of mainly mild character. The new harmonized definition of the metabolic syndrome was used in the multivariable logistic regression analysis.ResultsThere was a uniformly higher prevalence of the metabolic syndrome in men and women with psoriasis compared to those without across all age groups. In women, psoriasis was associated with a 3.8 times higher odds of metabolic syndrome at age 30 (95% confidence interval, CI 1.5-9.7) with a decreasing odds ratio with increasing age. In men, psoriasis was associated with a stable 1.35 times higher odds of metabolic syndrome (95% CI 1.1-1.6) in all ages. Abdominal obesity was the most frequent metabolic syndrome component in women in this study, and there was indication of a dose-response relationship between psoriasis severity, indicated through treatment, and having a high waistline in women.Conclusions This study suggests age and gender variations in the risk of metabolic syndrome among individuals with psoriasis. Given the high prevalence of psoriasis and the significantly elevated burden of metabolic syndrome in this patient group, there may be a benefit from targeted screening of metabolic syndrome among individuals with psoriasis regardless of age and disease severity.This article is protected by copyright. All rights reserved.
    British Journal of Dermatology 07/2014; 172(2). DOI:10.1111/bjd.13288 · 4.28 Impact Factor
Show more